BRPI0811267B8 - variante de fenilalanina amônia-liase de anabaena variabilis, composição farmacêutica compreendendo dita variante e uso da mesma para a preparação de um medicamento para o tratamento de fenilcetonúria (pku) - Google Patents
variante de fenilalanina amônia-liase de anabaena variabilis, composição farmacêutica compreendendo dita variante e uso da mesma para a preparação de um medicamento para o tratamento de fenilcetonúria (pku)Info
- Publication number
- BRPI0811267B8 BRPI0811267B8 BRPI0811267A BRPI0811267A BRPI0811267B8 BR PI0811267 B8 BRPI0811267 B8 BR PI0811267B8 BR PI0811267 A BRPI0811267 A BR PI0811267A BR PI0811267 A BRPI0811267 A BR PI0811267A BR PI0811267 B8 BRPI0811267 B8 BR PI0811267B8
- Authority
- BR
- Brazil
- Prior art keywords
- variant
- pal
- phenylalanine ammonia
- pharmaceutical composition
- anabaena variabilis
- Prior art date
Links
- 108700023158 Phenylalanine ammonia-lyases Proteins 0.000 title abstract 4
- 241000078013 Trichormus variabilis Species 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 201000011252 Phenylketonuria Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/807,227 US7534595B2 (en) | 2006-06-12 | 2007-05-25 | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| US11/807,227 | 2007-05-25 | ||
| PCT/US2008/006661 WO2008153776A1 (en) | 2007-05-25 | 2008-05-23 | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using said compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0811267A2 BRPI0811267A2 (pt) | 2014-10-07 |
| BRPI0811267B1 BRPI0811267B1 (pt) | 2020-11-10 |
| BRPI0811267B8 true BRPI0811267B8 (pt) | 2021-05-25 |
Family
ID=39868905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0811267A BRPI0811267B8 (pt) | 2007-05-25 | 2008-05-23 | variante de fenilalanina amônia-liase de anabaena variabilis, composição farmacêutica compreendendo dita variante e uso da mesma para a preparação de um medicamento para o tratamento de fenilcetonúria (pku) |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US7534595B2 (enExample) |
| EP (2) | EP2152868B1 (enExample) |
| JP (1) | JP5670183B2 (enExample) |
| KR (2) | KR101603796B1 (enExample) |
| CN (1) | CN101842482B (enExample) |
| AR (2) | AR066716A1 (enExample) |
| AU (1) | AU2008263190B2 (enExample) |
| BR (1) | BRPI0811267B8 (enExample) |
| CA (1) | CA2687450C (enExample) |
| CL (1) | CL2008001497A1 (enExample) |
| CY (2) | CY1116894T1 (enExample) |
| DK (1) | DK2152868T3 (enExample) |
| EA (1) | EA018443B1 (enExample) |
| ES (1) | ES2551315T3 (enExample) |
| HR (1) | HRP20151268T1 (enExample) |
| HU (2) | HUE025784T2 (enExample) |
| IL (1) | IL202132A (enExample) |
| LT (1) | LTC2152868I2 (enExample) |
| LU (1) | LUC00133I2 (enExample) |
| MX (1) | MX2009012453A (enExample) |
| MY (1) | MY151413A (enExample) |
| NL (1) | NL301011I2 (enExample) |
| NO (1) | NO2019037I1 (enExample) |
| PE (1) | PE20090315A1 (enExample) |
| PL (1) | PL2152868T3 (enExample) |
| PT (1) | PT2152868E (enExample) |
| SI (1) | SI2152868T1 (enExample) |
| TW (1) | TWI418633B (enExample) |
| WO (1) | WO2008153776A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7534595B2 (en) | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| US7531341B1 (en) | 2006-06-12 | 2009-05-12 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| US7537923B2 (en) * | 2007-08-17 | 2009-05-26 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
| WO2010014225A2 (en) * | 2008-07-30 | 2010-02-04 | Biomarin Pharmaceutical Inc. | Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase |
| EP4062928A3 (en) | 2010-02-04 | 2022-11-30 | BioMarin Pharmaceutical Inc. | Prokaryotic phenylalanine ammonia-lyases and their use for treating phenylketonuria and hyperphenylalaninemia |
| EP3222288A1 (en) * | 2012-07-27 | 2017-09-27 | University of North Texas | Genetically modified probiotic for the treatment of phenylketonuria (pku) disease |
| PL2986722T3 (pl) | 2013-04-18 | 2019-10-31 | Codexis Inc | Skonstruowane polipeptydy amoniakoliazy fenyloalaniny |
| BR112016011195A2 (pt) | 2013-11-18 | 2017-09-19 | Rubius Therapeutics Inc | Células eritroides enucleadas e seus métodos de fabricação, composição farmacêutica e seu uso, uso de uma população de células eritroides, biorreator, mistura de células e dispositivo médico |
| CN106456744A (zh) | 2014-04-01 | 2017-02-22 | 鲁比厄斯治疗法股份有限公司 | 用于免疫调节的方法和组合物 |
| EP3145536B1 (en) | 2014-04-16 | 2021-10-27 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| CA2970638A1 (en) | 2014-12-22 | 2016-06-30 | Codexis, Inc. | Human alpha-galactosidase variants |
| TW202440903A (zh) | 2015-08-04 | 2024-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法（一） |
| JP6994018B2 (ja) | 2016-07-26 | 2022-01-14 | バイオマリン ファーマシューティカル インコーポレイテッド | 新規アデノ随伴ウイルスキャプシドタンパク質 |
| CN109844127B (zh) * | 2016-08-30 | 2023-09-19 | 三菱化学株式会社 | 突变型酶的制造方法及突变型醇酰基转移酶 |
| CN106497905A (zh) * | 2016-12-14 | 2017-03-15 | 江南大学 | 一株鱼腥藻来源的苯丙氨酸脱氨酶的突变体 |
| AU2018217495B2 (en) * | 2017-02-13 | 2021-03-04 | Codexis, Inc. | Engineered phenylalanine ammonia lyase polypeptides |
| CN107653275A (zh) * | 2017-10-30 | 2018-02-02 | 安徽工程大学 | D‑苯丙氨酸的制备方法 |
| CN108004225B (zh) * | 2017-12-19 | 2020-05-08 | 江南大学 | 一种成团泛菌来源的苯丙氨酸氨基变位酶的突变体 |
| KR20210008501A (ko) | 2018-05-09 | 2021-01-22 | 바이오마린 파머수티컬 인크. | 페닐케톤뇨증을 치료하는 방법 |
| TW202005978A (zh) | 2018-05-14 | 2020-02-01 | 美商拜奧馬林製藥公司 | 新穎肝靶向腺相關病毒載體 |
| EP3807409A4 (en) | 2018-06-12 | 2022-08-03 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| EP3820833A4 (en) * | 2018-07-12 | 2022-08-03 | Codexis, Inc. | MODIFIED AMMONIA-LYASE PHENYLALANINE POLYPEPTIDES |
| AU2019397401A1 (en) | 2018-12-14 | 2021-06-17 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| MY207075A (en) | 2018-12-20 | 2025-01-28 | Codexis Inc | Human alpha-galactosidase variants |
| CN110456056A (zh) * | 2019-07-22 | 2019-11-15 | 浙江大学 | 一种新生儿苯丙酮尿症无创筛查试纸的制备方法 |
| BR112022003705A2 (pt) | 2019-08-30 | 2022-05-24 | Codexis Inc | Lipase recombinante, composição, sequência de polinucleotídeo recombinante, vetor de expressão, composição farmacêutica para o tratamento de insuficiência pancreática, célula hospedeira, métodos para produzir uma lipase recombinante e para tratar e/ou prevenir os sintomas de insuficiência pancreática, e, uso |
| MX2022007399A (es) | 2019-12-20 | 2022-09-19 | Codexis Inc | Variantes de alfa-glucosidasa ácida diseñadas. |
| EP4103711A4 (en) | 2020-02-04 | 2024-02-28 | Codexis, Inc. | Engineered leucine decarboxylases |
| WO2021168060A1 (en) * | 2020-02-19 | 2021-08-26 | Trustees Of Tufts College | Methods for engineering amino acid ammonia lyase enzymes and enzymes thereby obtained |
| TW202144575A (zh) | 2020-04-03 | 2021-12-01 | 美商拜奧馬林製藥公司 | 使用ａａｖ及治療調配物之苯酮尿症治療 |
| JP2023539634A (ja) | 2020-08-28 | 2023-09-15 | コデクシス， インコーポレイテッド | 操作されたアミラーゼバリアント |
| AU2021334371A1 (en) | 2020-08-28 | 2023-03-09 | Codexis, Inc. | Engineered protease variants |
| WO2022245924A1 (en) * | 2021-05-19 | 2022-11-24 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects |
| AU2022279241A1 (en) | 2021-05-21 | 2023-11-30 | Syntis Bio, Inc. | Engineered methionine gamma lyase variants |
| WO2023044381A1 (en) * | 2021-09-16 | 2023-03-23 | Arcturus Therapeutics, Inc. | Compositions and methods for treating phenylketonuria |
| JP2024540358A (ja) | 2021-11-01 | 2024-10-31 | シンティス バイオ，インコーポレイティド | 工学操作ロイシン脱炭酸酵素 |
| CN117417925A (zh) * | 2022-07-18 | 2024-01-19 | 浙江泽科塔生物医药有限公司 | Pal变体、包含该pal变体的药物组合物以及用于制备该pal变体的方法 |
| CN118931888A (zh) * | 2023-05-09 | 2024-11-12 | 重庆派金生物科技有限公司 | 苯丙氨酸裂解酶突变体及其偶联物或其药学上可接受的盐 |
| GB202307239D0 (en) | 2023-05-15 | 2023-06-28 | Evox Therapeutics Ltd | Gene therapies for Phenylketonuria |
| CN116478975B (zh) * | 2023-06-16 | 2023-09-01 | 苏州优信合生技术有限公司 | 高活性苯丙氨酸解氨酶突变体及其表达菌株 |
| WO2025106759A1 (en) | 2023-11-17 | 2025-05-22 | Biomarin Pharmaceutical Inc. | Conjugates of phenylalanine ammonia-lyase and poegma and methods for their use |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4252822A (en) | 1979-12-26 | 1981-02-24 | Children's Hospital Medical Center | Method for treating phenylketonuria |
| US4562151A (en) | 1983-09-06 | 1985-12-31 | Monsanto Company | Stabilization of L-phenylalanine ammonia-lyase enzyme |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| WO1994013817A1 (en) | 1992-12-04 | 1994-06-23 | Me Medical Enzymes Ag | Genetically engineered glutaminase and its use in antiviral and anticancer therapy |
| JP2930723B2 (ja) | 1992-11-19 | 1999-08-03 | アンティキャンサー インコーポレーテド | 抗メチオニン化学療法における抗腫瘍薬としてのメチオニナーゼの使用 |
| DK75593D0 (enExample) | 1993-06-25 | 1993-06-25 | Novo Nordisk As | |
| JPH09510352A (ja) * | 1994-03-15 | 1997-10-21 | プリズム ファーマシューティカルズ，インコーポレイティド | 遺伝子療法及び前部の眼疾患のためのヘパリン結合成長因子 |
| ATE455171T1 (de) | 1995-09-21 | 2010-01-15 | Genentech Inc | Varianten des menschlichen wachstumshormons |
| CU22585A1 (es) * | 1995-11-17 | 1999-11-03 | Centro Inmunologia Molecular | Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune. |
| US6548644B1 (en) | 1997-03-10 | 2003-04-15 | Immunex Corporation | Site protected protein modification |
| US6183738B1 (en) | 1997-05-12 | 2001-02-06 | Phoenix Pharamacologics, Inc. | Modified arginine deiminase |
| US5981239A (en) | 1997-09-24 | 1999-11-09 | Great Lakes Chemical Corp. | Synthesis of optically active phenylalanine analogs using Rhodotorula graminis |
| US7026446B1 (en) * | 1997-12-24 | 2006-04-11 | Diatech Pty Ltd. | Bifunctional molecules |
| TWI227241B (en) * | 1998-06-20 | 2005-02-01 | United Biomedical Inc | IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate |
| US6451986B1 (en) | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
| US6461849B1 (en) | 1998-10-13 | 2002-10-08 | Novozymes, A/S | Modified polypeptide |
| US6403312B1 (en) | 1998-10-16 | 2002-06-11 | Xencor | Protein design automatic for protein libraries |
| US6686164B1 (en) | 1998-10-30 | 2004-02-03 | Novozymes A/S | Low allergenic protein variants |
| CA2328614C (en) | 1999-02-12 | 2012-06-26 | Biostream, Inc. | Matrices for drug delivery and methods for making and using the same |
| WO2001041782A2 (en) * | 1999-12-09 | 2001-06-14 | Chiron Corporation | Method for administering a cytokine to the central nervous system and the lymphatic system |
| US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
| EP1280924A2 (en) | 2000-04-14 | 2003-02-05 | University of South Carolina Research Foundation | Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses |
| US6967097B2 (en) | 2000-07-24 | 2005-11-22 | Pcbu Services, Inc. | Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same |
| EP1309705B1 (en) * | 2000-07-25 | 2012-02-15 | Immunomedics Inc. | Multivalent target binding protein |
| WO2002026028A2 (en) * | 2000-09-26 | 2002-04-04 | The Regents Of The University Of California | Characterization of phenylalanine ammonia-lyase (pal) gene in wounded lettuce |
| WO2002038609A2 (en) * | 2000-11-10 | 2002-05-16 | Proteopharma Aps | Apolipoprotein conjugates |
| JP4722396B2 (ja) | 2002-02-26 | 2011-07-13 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 遺伝要素の組換え方法 |
| AU2003246690B2 (en) * | 2002-07-17 | 2010-03-11 | Cytos Biotechnology Ag | Molecular antigen arrays using a virus like particle derived from the AP205 coat protein |
| JP2006516095A (ja) | 2002-11-14 | 2006-06-22 | ザ スクリップス リサーチ インスティテュート | 脂肪酸アミドヒドロラーゼ（ｆａａｈ）の結晶形 |
| AU2004247737B2 (en) * | 2003-06-11 | 2009-04-23 | Wyeth | Platelet glycoprotein IB alpha variant fusion polypeptides and methods of use thereof |
| FR2868318B1 (fr) * | 2004-04-01 | 2012-11-16 | Commissariat Energie Atomique | Antigene tat stabilise et ses applications pour la vaccination anti-vih |
| US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| AU2005286763A1 (en) | 2004-09-17 | 2006-03-30 | Biomarin Pharmaceutical, Inc. | Variants and chemically-modified variants of phenylalanine ammonia-lyase |
| EP1869174B1 (en) | 2005-03-10 | 2015-02-18 | BASF Enzymes LLC | Lyase enzymes, nucleic acids encoding them and methods for making and using them |
| US7534595B2 (en) * | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| WO2008069958A2 (en) | 2006-12-01 | 2008-06-12 | The Salk Institute For Biological Studies | Substrate switched ammonia lyases and mutases |
| US7537923B2 (en) | 2007-08-17 | 2009-05-26 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
-
2007
- 2007-05-25 US US11/807,227 patent/US7534595B2/en active Active
-
2008
- 2008-05-23 CL CL2008001497A patent/CL2008001497A1/es unknown
- 2008-05-23 AR ARP080102198A patent/AR066716A1/es active IP Right Grant
- 2008-05-23 JP JP2010509405A patent/JP5670183B2/ja active Active
- 2008-05-23 PT PT87547170T patent/PT2152868E/pt unknown
- 2008-05-23 BR BRPI0811267A patent/BRPI0811267B8/pt active IP Right Grant
- 2008-05-23 PE PE2008000889A patent/PE20090315A1/es active IP Right Grant
- 2008-05-23 ES ES08754717.0T patent/ES2551315T3/es active Active
- 2008-05-23 MX MX2009012453A patent/MX2009012453A/es active IP Right Grant
- 2008-05-23 EP EP08754717.0A patent/EP2152868B1/en active Active
- 2008-05-23 CA CA2687450A patent/CA2687450C/en active Active
- 2008-05-23 HU HUE08754717A patent/HUE025784T2/en unknown
- 2008-05-23 PL PL08754717T patent/PL2152868T3/pl unknown
- 2008-05-23 HR HRP20151268TT patent/HRP20151268T1/hr unknown
- 2008-05-23 DK DK08754717.0T patent/DK2152868T3/en active
- 2008-05-23 CN CN200880016898.4A patent/CN101842482B/zh active Active
- 2008-05-23 EP EP13169362.4A patent/EP2657335A1/en not_active Withdrawn
- 2008-05-23 MY MYPI20094868 patent/MY151413A/en unknown
- 2008-05-23 KR KR1020097027018A patent/KR101603796B1/ko active Active
- 2008-05-23 SI SI200831540T patent/SI2152868T1/sl unknown
- 2008-05-23 EA EA200970980A patent/EA018443B1/ru unknown
- 2008-05-23 TW TW097119178A patent/TWI418633B/zh active
- 2008-05-23 WO PCT/US2008/006661 patent/WO2008153776A1/en not_active Ceased
- 2008-05-23 KR KR20157007821A patent/KR20150038753A/ko not_active Ceased
- 2008-05-23 AU AU2008263190A patent/AU2008263190B2/en active Active
-
2009
- 2009-11-15 IL IL202132A patent/IL202132A/en active IP Right Grant
-
2015
- 2015-11-06 CY CY20151100997T patent/CY1116894T1/el unknown
-
2018
- 2018-01-17 AR ARP180100106A patent/AR110834A2/es unknown
-
2019
- 2019-10-09 NL NL301011C patent/NL301011I2/nl unknown
- 2019-10-10 LT LTPA2019517C patent/LTC2152868I2/lt unknown
- 2019-10-14 LU LU00133C patent/LUC00133I2/fr unknown
- 2019-10-16 NO NO2019037C patent/NO2019037I1/no unknown
- 2019-10-17 CY CY2019039C patent/CY2019039I2/el unknown
- 2019-10-18 HU HUS1900049C patent/HUS1900049I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0811589B8 (pt) | composição farmacêutica, e, usos de uma composição farmacêutica | |
| WO2011097335A3 (en) | Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof | |
| MX2009012453A (es) | Composiciones de amoniaco-liasa de fenilalanina procariotica y metodos de uso de dichas composiciones. | |
| BR112015014457A2 (pt) | composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c | |
| MX2009004745A (es) | Derivados de 1,2,3-triazol como inhibidores del receptor sigma. | |
| WO2008075371A3 (en) | T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation | |
| MX390627B (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| GT200800184A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes. | |
| MY150958A (en) | Compounds for the treatment of multi-drug resistant bacterial infections | |
| EA200802166A1 (ru) | Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью | |
| MX2010005631A (es) | Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades. | |
| MX2007008924A (es) | Compuestos quimicos. | |
| TW200806300A (en) | New therapeutic combinations for the treatment of depression | |
| MY138708A (en) | Biaryloxymethylarenecarboxylic acids | |
| MX2009004561A (es) | Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor. | |
| WO2010111640A3 (en) | Anti-influenza formulations and methods | |
| MX2011008899A (es) | Nuevas orto-aminoamidas para el tratamiento del cancer. | |
| BR112012015202A2 (pt) | "iota - e/ou kappa-carrgenado junto com um inibidor da neuraminidase, método para o tratamento profilático ou terapêutico de um sintoma, condição ou doença, composição farmacêutica,e, kit de partes". | |
| MY164864A (en) | Indenone derivative and pharmaceutical composition comprising same | |
| ECSP066608A (es) | Suspensiones acuosas de ciclesonide para nebulización | |
| BR112012022209A2 (pt) | composições farmacêuticas compreendendo monoterpenos | |
| MA32406B1 (fr) | Composés contenant de l'azote tricyclique et utilisation de ceux-ci comme antibactériens | |
| UA106907C2 (uk) | Стабілізована фармацевтична композиція | |
| GEP20135832B (en) | Benzothiazines derivatives, preparation thereof, and their application as drugs | |
| MX2008011020A (es) | Compuestos de receptor sigma. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 38/01 (1995.01), C12N 9/88 (1980.01) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/11/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/05/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |